PHARMA SIGNALOPEN RESEARCH PLATFORM →
COMPANY RESEARCH PROFILE · UPDATED 2026-09-29

Keymed Biosciences

Biotechnology company developing antibody therapies for autoimmune disease and oncology.

TICKER2162.HK
HEADQUARTERSChengdu, China
STAGEApproved
ACTIVE TRIALS27

Therapeutic areas

AutoimmuneOncology

Selected products and programs

stapokibartCMG901

Linked curated drug profiles

No curated drug entity is linked in the current pilot.

Selected active clinical trials

Study of Stapokibatrt in Children Subjects With Atopic Dermatitis

Phase 3 · Not Yet Recruiting · Atopic Dermatitis

Study of CM559 in Healthy Subjects

Phase 1 · Recruiting · Healthy Subjects

Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Phase 2 · Recruiting · Primary Light-Chain Amyloidosis

Study of CM383 in Healthy Subjects

Phase 1 · Recruiting · Healthy

Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis

Phase 2 · Recruiting · Atopic Dermatitis

Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU)

Phase 2 · Recruiting · Chronic Spontaneous Urticaria (CSU)

Selected patent records

No linked FDA Orange Book patent record was found for the selected products.

Primary and company sources

Company and pipeline information can change. Verify material decisions against the linked primary sources.

Evidence & limits

Source: Open the source record

Record identifier
/companies/keymed-biosciences/
Event / action date
Not separately retained
Source update date
Not separately retained
Platform retrieval / processing date
Not separately retained

What it supports. Connections found through the catalog, identifiers, or name and alias matching, with source links where retained.

Limits. A company association is not proof of ownership or sponsorship of every linked record. Product, substance, parent-company, and subsidiary relationships may differ.

Connection basis. Catalog, identifier, or normalized name association. Product and company connections are research leads, not ownership determinations.

What this record means · Report an issue with this record